This inventor holds 1 USPTO granted patent. Top assignee: Wakamoto Pharmaceutical Co., Ltd.. Active years: 1982.
Company Filing History:
Years Active: 1982
Title: Kenichi Edanami: Innovator in Antitumor Compounds
Introduction
Kenichi Edanami is a notable inventor based in Kamakura, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antitumor agents. His innovative work focuses on creating compounds that offer therapeutic benefits with reduced side effects.
Latest Patents
Kenichi Edanami holds a patent for a D-Allose derivative and its preparation method. The patent, titled "3-[3-(2-Haloethyl)-3-nitrosoureido]-3-deoxy-D-alloses," describes new antitumor compounds that exhibit far lower myelotoxicity compared to conventional antitumor agents. These compounds are synthesized by treating 3-[3-(2-haloethyl)ureido]-3-deoxy-1,2,5,6-di-O-isopropylidene-α-D-allofuranoses with a nitrosating agent, followed by hydrolysis of the protective group in the presence of an acid. This innovative approach has the potential to improve cancer treatment outcomes.
Career Highlights
Kenichi Edanami is associated with Wakamoto Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work has garnered attention for its focus on creating safer and more effective treatment options for patients battling cancer.
Collaborations
Throughout his career, Kenichi has collaborated with esteemed colleagues, including Masahide Yamada and Toshio Kuroda. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his research.
Conclusion
Kenichi Edanami's contributions to the field of pharmaceuticals, particularly in the development of antitumor compounds, highlight his innovative spirit and dedication to improving patient care. His work exemplifies the importance of research in creating safer treatment alternatives for cancer patients.